Bachem Holding AG Stock Swiss Exchange
Equities
BANB
CH0012530207
Biotechnology & Medical Research
Sales 2024 * | 620M 674M | Sales 2025 * | 811M 882M | Capitalization | 6.01B 6.53B |
---|---|---|---|---|---|
Net income 2024 * | 127M 138M | Net income 2025 * | 160M 174M | EV / Sales 2024 * | 9.59 x |
Net cash position 2024 * | 64.89M 70.55M | Net Debt 2025 * | 74.85M 81.36M | EV / Sales 2025 * | 7.5 x |
P/E ratio 2024 * |
50
x | P/E ratio 2025 * |
37.9
x | Employees | 2,006 |
Yield 2024 * |
1.07% | Yield 2025 * |
1.16% | Free-Float | 94.31% |
Latest transcript on Bachem Holding AG
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 18-12-31 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 12-04-24 |
Director/Board Member | 51 | 11-04-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 18 M€ | +4.21% | - |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |